FONS Nové sekvenační technologie vklinickédiagnostice?

Similar documents
The Human Major Histocompatibility Complex

Characterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser

Advance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library

Genomic Medicine: What every pathologist needs to know

CMS will not implement the new tier codes for Medicare/Medicaid claims for calendar year 2012.

CPT Codes for Pharmacogenomic Tests

Significance of the MHC

Cytogenetics 101: Clinical Research and Molecular Genetic Technologies

Evaluation of MIA FORA NGS HLA test and software. Lisa Creary, PhD Department of Pathology Stanford Blood Center Research & Development Group

2/10/2016. Evaluation of MIA FORA NGS HLA test and software. Disclosure. NGS-HLA typing requirements for the Stanford Blood Center

Accel-Amplicon Panels

Fluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS

Completing the CIBMTR Confirmation of HLA Typing Form (Form 2005)

Developments in Laboratory Genetics

ASSESSMENT OF THE RISK FOR TYPE 1 DIABETES MELLITUS CONFERRED BY HLA CLASS II GENES. Irina Durbală

AG MHC HLA APC Ii EPR TAP ABC CLIP TCR

Histocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director

Molecular Diagnostics Overview JAN A. NOWAK, PHD, MD PATHOLOGY AND LABORATORY MEDICINE MOLECULAR DIAGNOSTICS LABORATORY FEBRUARY 15, 2018

Significance of the MHC

Profiling HLA motifs by large scale peptide sequencing Agilent Innovators Tour David K. Crockett ARUP Laboratories February 10, 2009

Validation of the MIA FORA NGS FLEX Assay Using Buccal Swabs as the Sample Source

Abstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction

EXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)

An innovative multi-dimensional NGS approach to understanding the tumor microenvironment and evolution

Genetic Testing for Pharmacogenetics

NGS in tissue and liquid biopsy

Significance of the MHC

HLA and new technologies. Vicky Van Sandt

HLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol

SureSelect Cancer All-In-One Custom and Catalog NGS Assays

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R

Genetic Screening for ADR

IMMUNOLOGY. Elementary Knowledge of Major Histocompatibility Complex and HLA Typing

Yes if indicated below. (4.0 TMPT does not require prior authorization)

New: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix.

Applications of Chromosomal Microarray Analysis (CMA) in pre- and postnatal Diagnostic: advantages, limitations and concerns

Calculation Tables. Olerup SSP Kits without Taq Polymeras

HLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol

a) SSR with core motif > 2 and repeats number >3. b) MNR with repeats number>5.

AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits

Exosome DNA Extraction Kits

Using the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep

Calculation Tables. Olerup SSP Kits without Taq Polymeras

Transform genomic data into real-life results

Plasma-Seq conducted with blood from male individuals without cancer.

MRC-Holland MLPA. Description version 08; 30 March 2015

Lynch Syndrome and COLARIS Testing

MEDICAL GENOMICS LABORATORY. Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG)

Mutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research

the HLA complex Hanna Mustaniemi,

ASHI Proficiency Testing Program Summary Report. Survey 2013-HT1 / HLA Typing

Association mapping (qualitative) Association scan, quantitative. Office hours Wednesday 3-4pm 304A Stanley Hall. Association scan, qualitative

MEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)

CS2220 Introduction to Computational Biology

Molecular Testing in Lung Cancer

Diversity and Frequencies of HLA Class I and Class II Genes of an East African Population

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT

Structural Variation and Medical Genomics

Liquid biopsy in lung cancer: The EGFR paradigm

SALSA MLPA probemix P315-B1 EGFR

Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy

Enabling Personalized

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers

MEDICAL POLICY. SUBJECT: MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES (Excluding NSCLC and CRC) EFFECTIVE DATE: 12/21/17

IntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.

DEFINITIONS OF HISTOCOMPATIBILITY TYPING TERMS

Please Silence Your Cell Phones. Thank You

MRC-Holland MLPA. Related SALSA MLPA probemixes P190 CHEK2: Breast cancer susceptibility, genes included: CHEK2, ATM, PTEN, TP53.

10/18/2012. A primer in HLA: The who, what, how and why. What?

Genetics and Genomics in Medicine Chapter 8 Questions

Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers

Generating Spontaneous Copy Number Variants (CNVs) Jennifer Freeman Assistant Professor of Toxicology School of Health Sciences Purdue University

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

Genomic structural variation

AVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT MARCH 13, 2012

DOES THE BRCAX GENE EXIST? FUTURE OUTLOOK

Personalized Genetics

Supplementary note: Comparison of deletion variants identified in this study and four earlier studies

CNV detection. Introduction and detection in NGS data. G. Demidov 1,2. NGSchool2016. Centre for Genomic Regulation. CNV detection. G.

Nature Biotechnology: doi: /nbt.1904

Genetics and Genomics: Influence on Individualization of Medication Regimes

Protein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies

α chain β chain C N C N β 2 α 1 β 1 α 2

Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San

SALSA MLPA KIT P050-B2 CAH

MRC-Holland MLPA. Description version 18; 09 September 2015

MET skipping mutation, EGFR

DNA-seq Bioinformatics Analysis: Copy Number Variation

Trends in molecular diagnostics

Supplementary Figure 1

Personalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making

NEXT GENERATION SEQUENCING AND TRANSLATIONAL RESEARCH: The Express Lane from Bench to Bedside 9 May, 2012

The Biology and Genetics of Cells and Organisms The Biology of Cancer

A complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis

7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview

NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation

Supporting Online Material for

Analysis with SureCall 2.1

Transcription:

FONS 2010 Nové sekvenační technologie vklinickédiagnostice?

Sekvenování amplikonů Sequence capture Celogenomové sekvenování

FONS 2010 Sekvenování amplikonů

Amplicon sequencing - amplicon sequencing enables the identification and quantification of known and novel sequence variations within complex mixtures of PCR products - reads are compared to a user defined reference sequence to identify and quantify known variants and facilitate the discovery of novel variants. - detection of rare sequence variants in a complex sample (e.g. cancer studies) - population studies to find rare alleles - investigation of diversity in environmental samples - investigation of diversity in clinical research studies

Comparison Sanger and NGS Sequenced Based Typing Resolution of Ambiguity T T C T Sanger Sequencing T C T T Population sequencing = mixed reads sensitivity ~ 15% T T C T T T NGS Sequencing T T T T T C Clonal sequencing = 1 DNA = 1 read sensitivity < 1%

HIV resistance testing 3 mutations are frequently observed in multidrug resistant HIV viruses: M46I/L, V82A/F/S/T, and L90M - The combination confers resistance to all protease inhibitors currently in use If all three were found on a single major species before treatment, protease inhibitors would have minimal effect However, if they were on distinct species, they could be suppressed by different inhibitors

HIV resistance testing

Effective Detection of Low Frequency Drug Resistance Mutations in HIV at a 1% level Detection of low frequency mutations conferring resistance to HIV drugs Mutations -Type -Frequency C984A 2.7% D177E T990G 5.8% no Δ C993A 2.3% no Δ C993T 2.2% no Δ A995G 1.0% Y181C T996C 0.9% no Δ C1002T 0.5% no Δ T1012C 0.4% no Δ D177E: common polymorphism (20% of clade B viruses) Reference Sequence

HLA Region (Human Leukocyte Antigen) (Chromosome 6p) DP DM TAP DQ DR TNF B C A 150 kb 50 kb 200 kb 50 kb 850 kb 250 kb 100 kb 1270 kb B1 A1 B A 1 2 B1 A1 B1 B3 A1 B4 B5 10835 138 28 785 52 14 19 3 A B 1605 690 1001 6 9 25 68 10 28 Green = serotypes class II loci class I loci The HLA region is the most polymorphic region of the human genome 4,478 alleles at 12 loci as of May 2010

Molecular Targets of HLA Typing SJ Lee, et al. Blood 2007

HLA Disease Associations (selected examples) Autoimmunity / Inflammation IDDM (type 1 diabetes) MS IBD (UC and CD) RA, juvenile RA Pemphigus Vulgaris MG Ankylosing Spondylitis Psoriasis Celiac Disease Unknown Narcolepsy Cancer Cervical Carcinoma NP Carcinoma HD Infectious Disease Malaria Tuberculosis Leprosy HCV HIV Drug Allergic Hypersensitivity Abacavir carbamizine

HLA sequencing CLASS I class II class I exons 2, 3 and 4 from HLA-A exons 2, 3 and 4 from HLA-B exons 2, 3 and 4 from HLA-C blue exons 8 primer pairs & red exons 6 primer pairs MIDs MIDs CLASS II Medium High exon 2 from DPB1 Resolution Resolution exon 2 from DQA1 exons 2 and 3 from DQB1 exon 2 from DRB1

Conexio ATF Genotype of HLA-B

Amplicon Sequencing Major research applications will include the discovery and verification of causative mutations for mono or multi genetic disorders somatic mutations in cancer Technology of choice to substitute Sanger Sequencing in Clinical Research Predisposition testing like syndroms (blindness, deafness), breast cancer (BRCA etc) Patient stratification: EGFR, KRAS, BRAF, PIK3CA, ERBB2, NRAS, HRAS, PTEN, KIT, PDGFRA Technology of choice for Diagnostic Sequencing HIV, HLA etc

FONS 2010 Sequence capture

SEQUENCE CAPTURE

Key Driver is Complexity Reduction Sequencing Sample Preparation Sequencing Sample Preparation? Capillary Sequencing PCR Next-Gen Sequencing PCR Complexity reduction by enrichment of smaller genomic portion will exploit the full potential of next-generation sequencing instruments

NimbleGen Sequence Capture Exon1 Exon2 Exon3 Exon4 Exon5 Exon6 Fragment & Add Linkers Genomic DNA hybridize Wash Background DNA Probes Target DNA Elute Amplification Target DNA Array NGS Sequencing

Agilent Sequence Capture

Sequence Capture Targeting the 11p12 Diabetes Locus NimbleGen Sequence Capture array: 385,000 probes targeted ~3 Mb 72% of the region covered by probes Repetitive regions

Benefit of Sequence Capture Time Saved (vs. LR-PCR) Cost Saved (vs. parallel PCR) 700 600 Long Range PCR $30,000 $25,000 PCR cost / sample (10 sample project) PCR cost / sample (100 sample project) Work Days Needed 500 400 300 200 Sequence Capture Cost / Sample $20,000 $15,000 $10,000 Sequence capture cost / sample 100 $5,000 0 10 100 1000 10000 Size of Region (Kb) $0 100 1000 10000 100000 # of Exons SeqCap offers customer with significant savings in time and cost.

FONS 2010 Celogenomové sekvenování

Proc. Natl. Acad. Sci. U. S. A. 105, 20458-20463

Proc. Natl. Acad. Sci. U. S. A. 105, 20458-20463 The z-score of a potentially aneuploid chromosome is expected to be higher for pregnancies with an aneuploid fetus (cases E H shown in green) than for those with a euploid fetus (cases A D shown in blue).

Stephen R Quake Stephen Quake, D.Phil. Professor of Bioengineering Co-Chair, Department of Bioengineering Investigator, Howard Hughes Medical Institute D. Phil., Physics, University of Oxford, 1994. MS, Mathematics, Stanford University, 1991. BS, Mathematics, Stanford University, 1991

Clinical assessment incorporating a personal genome Lancet 2010; vol. 375: 1525-1535

Clinical characteristics of the patient

Patient pedigree

Approach to variants

Clinical risk incorporating genetic-risk estimates for major diseases Pre-test probabilities or disease prevalence (in white men in the patient s age range) - backs of the arrowheads show pre-test probabilities -arrows point in the direction of change in probability - blue lines show lowered posttest probabilities - red lines increased post-test probabilities n=number of independent single nucleotide polymorphisms used in calculation of post-test probability for that disorder

Contribution of individual alleles to overall risk of prostate cancer

Contribution of individual alleles to overall risk of Alzheimer s disease

Findings & Interpretation analysis of 2 6 million single nucleotide polymorphisms and 752 copy number variations increased genetic risk for myocardial infarction, type 2 diabetes, and some cancers we discovered rare variants in three genes that are clinically associated with sudden cardiac death TMEM43, DSP, and MYBPC3 a variant in LPA was consistent with a family history of coronary artery disease the patient had a heterozygous null mutation in CYP2C19 suggesting probable clopidogrel resistance, several variants associated with a positive response to lipid-lowering therapy, and variants in CYP4F2 and VKORC1 that suggest he might have a low initial dosing requirement for warfarin many variants of uncertain importance were reported Although challenges remain, our results suggest that whole-genome sequencing can yield useful and clinically relevant information for individual patients

Lancet 2010; vol. 376: 869

NATURE, 2010, vol. 464: 1351-1358

Lancet 2010, vol. 375:

FONS 2010 Děkuji za pozornost. Dotazy?